In Vivo Sp. z o.o.

At In Vivo Sp. z o.o. in Bydgoszcz, clinical research in cardiovascular diseases focuses on reducing serious heart and stroke-related events in people at elevated risk. The studies are designed to assess whether new approaches can better prevent complications linked to atrial fibrillation and early atherosclerotic cardiovascular disease.

• Testing a new option for preventing major cardiovascular events in high-risk patients
• Evaluating protection against stroke and systemic embolism in atrial fibrillation
• Studying therapies aimed at improving primary prevention of ASCVD

This area combines treatment effectiveness research with prevention-focused care, helping clarify whether emerging therapies can lower long-term cardiovascular risk.

The site is also active in respiratory tract diseases, with trials centered on infections that can be especially serious in infants, children, and older adults. Research here includes RSV infection, influenza, and pneumococcal infection, with attention to both treatment and prevention.

• Assessing new ways to prevent RSV-related lower respiratory illness
• Evaluating safety and tolerability of treatments for RSV lower respiratory tract infection
• Studying antiviral susceptibility and transmission patterns in influenza
• Reviewing vaccine approaches for protection against invasive pneumococcal disease

These studies aim to improve prevention, support better infection control, and expand options for managing respiratory illnesses.

Clinical trials in nutritional and metabolic diseases at this research site include work on type 2 diabetes mellitus and broader cardiovascular-metabolic risk reduction. The research is focused on whether new treatments can improve blood sugar control while remaining safe and well tolerated.

• Evaluating a therapy for better HbA1c control in type 2 diabetes
• Monitoring safety and tolerability in ongoing metabolic care research
• Exploring treatment strategies that may also support long-term health outcomes

This work reflects a practical interest in improving day-to-day diabetes management and reducing the wider health burden linked to metabolic disease.

Research in bacterial infections and mycoses includes vaccine-focused studies aimed at preventing serious infections, especially those that can lead to hospitalization or invasive disease. At In Vivo Sp. z o.o., this area is represented by work on pneumococcal infection prevention.

• Testing vaccine strategies to prevent invasive pneumococcal disease
• Comparing immune responses after vaccination
• Assessing safety and tolerability of preventive infection-control approaches

The goal is to strengthen protection against serious bacterial illness through improved preventive care.

Trials linked to immune system processes at this site examine how the body responds to vaccination and infection-related interventions. These studies help researchers understand immune protection against respiratory and bacterial threats, including RSV and pneumococcal disease.

• Measuring immune response after vaccination
• Studying protection against infection in vulnerable populations
• Supporting development of better preventive therapies

This research is important for identifying approaches that may improve immune defense and reduce the risk of severe infectious disease.

The site’s environment and public health research reflects a broader preventive focus, with studies aimed at reducing disease burden in the community. These trials address infections and chronic conditions that affect public health, including respiratory viruses and cardiovascular risk.

• Preventing infection-related illness in infants and children
• Reducing community impact of influenza and RSV
• Supporting early prevention of chronic disease complications

This portfolio shows an emphasis on practical health benefits, from lowering infection spread to improving long-term disease prevention.